Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.
One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.
For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions ...
Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.
Cherry angiomas (CAs), also known as Campbell de Morgan spots, are common, benign, well-demarcated cutaneous vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results